AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00514514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandimmun Optoral
Description: 1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
Study NCT00514514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmun Optoral
Description: 1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
Study NCT00514514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect®
Description: Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
Study NCT02288936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg/day
Study NCT00428909 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib/Acetaminophen
Study NCT02471703 — intervention group
Intervention type: DEVICE
Intervention: Total hip arthroplasty
Description: Total hip arthroplasty
Study NCT01424111 — intervention group
Intervention type: DRUG
Intervention: Escitalopram
Description: An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
Study NCT01424111 — intervention group
Intervention type: OTHER
Intervention: Healthy Control
Description: No Treatment
Study NCT03332498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 milligrams of pembrolizumab will be given through an IV (intravenously) for about thirty minutes. Pembrolizumab is an anti-PD1 that functions by inhibiting checkpoint inhibition and reversing T cell suppression.
Study NCT03332498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib oral capsules every day starting on cycle 1, day 1. Ibrutinib is primarily a BTK inhibitor which has been approved for the treatment of several hematologic malignancies.
Study NCT04185103 — intervention group
Intervention type: DRUG
Intervention: Sacubitril-Valsartan
Description: After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
Study NCT02554019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT063
Description: Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
Study NCT02554019 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
Study NCT02205203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mayo Clinic Anxiety Coach
Description: Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
Study NCT02205203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
Study NCT02828553 — intervention group
Intervention type: OTHER
Intervention: Aggressive planned ambulation with a mobility aide
Description: A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
Study NCT01513538 — intervention group
Intervention type: DEVICE
Intervention: TherapyGuide
Description: Use of TherapyGuide function to help programming the device
Study NCT01785160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: low dose oral administration
Study NCT01785160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: low dose oral administration
Study NCT01785160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: medium dose oral administration
Study NCT01901575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
Study NCT01908023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
Study NCT00779480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2449
Description: KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
Study NCT01021956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAKEL
Description: Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
Study NCT04182373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin gamma
Description: Intravenous infusion, once a day, 7 days
Study NCT04182373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: Intravenous infusion, once a day, 7 days
Study NCT01378507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: endoscopic submucosal dissection
Description: ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
Study NCT05578859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Single oral dose of AMG510.
Study NCT01239342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01239342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT01239342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT02302508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel, Prasugrel, Ticagrelor
Description: PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
Study NCT02302508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel, Prasugrel, Ticagrelor
Description: PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
Study NCT01305642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individualized fortification of breast milk
Description: Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis.
Study NCT00798850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull \& East Yorshire Yospitals NHS Trust.
Study NCT00798850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Programme (SEP)
Description: SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.~Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).~1. Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)~2. Station 2-Exercise bicycles~3. Station 3-Knee extensions with weights(2kg beanbag)~4. Station 4-Heel raises~5. Station 5-Knee bends(Alternating legs after 10 bends)~6. Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.~This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants.
Study NCT00798850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Treatment
Description: PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
Study NCT02151955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual
Description: 10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
Study NCT01848288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CENTURION® Vision System (CVS)
Description: Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
Study NCT01848288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CENTURION® Vision System (CVS)
Description: Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
Study NCT01848288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFINITI® Vision System (IVS)
Description: Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
Study NCT01848288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INFINITI® Vision System (IVS)
Description: Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
Study NCT02947672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Dexamethasone
Study NCT02947672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Dexamesathone
Study NCT00079404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT03066128 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care viral load testing
Description: Point-of-care viral load testing will be performed while the participant is in the clinic to ensure that participants receive the viral load results on the same day
Study NCT03066128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lab-based viral load testing
Description: Viral load testing will be lab based and follow standard of care procedures
Study NCT00733148 — intervention group
Intervention type: DRUG
Intervention: dosing of insulin
Description: Dosing od insulin is calculated by a computer based algorithm
Study NCT02289430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor+Ezetrol
Description: rosuvastatin+ezetimibe
Study NCT02289430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetrol
Description: ezetimibe
Study NCT02289430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor
Description: rosuvastatin
Study NCT03156920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT03156920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT02722538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Description: TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
Study NCT02590120 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition
Study NCT03023020 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Dosing per current guidelines and local practice
Study NCT03023020 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: P2Y12 inhibitor
Description: Dosing per current guidelines and local practice
Study NCT00794599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg (Clarinex)
Description: Clarinex 5 mg daily x 7 days
Study NCT00794599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Zyrtec 10 mg daily x 7 days
Study NCT00880399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orvepitant
Description: Neurokinin-1 (NK-1) antagonist
Study NCT00880399 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive placebo to match orvepitant 30 and 60 mg dosage forms
Study NCT01160757 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasound
Description: ultrasound exposure on acute acne lesions
Study NCT01922817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saxagliptin
Description: 5mg saxagliptin
Study NCT01922817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5mg saxagliptin
Study NCT03113240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamin
Description: Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
Study NCT03113240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin mixed with water given via NG tube q 4 hours.
Study NCT01399554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy plus Contingency Management
Description: A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
Study NCT04096027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline Pill
Description: 0.5 mg cabergoline pill taken orally
Study NCT01980537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wire navigation
Study NCT04114149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: TENS as first line of treatment. If insufficient pain relief, i.e. postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 after two treatment sessions à 1 minute, the patient receives conventional treatment with iv opioids.
Study NCT04114149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv opioid
Description: Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
Study NCT01427998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: olive leaf extract
Description: olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
Study NCT01427998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04474769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention for preceptors
Study NCT03443076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA + DHA in SMEDS Formulation
Description: A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
Study NCT03443076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza (active comparator; already FDA approved)
Description: A single dose of 840 mg EPA + DHA administered as Lovaza. This intervention was used as an active comparator in this study. Lovaza was already FDA-approved when the study was conducted.
Study NCT00139776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed.
Study NCT00139776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.
Study NCT02064530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 21 ml 0.5 %bupivacaine is applied interfasially
Study NCT02064530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
Study NCT02064530 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: serum physiologic
Description: 21 ml serum physiologic is applied interfasially
Study NCT03168776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme DES
Description: Implant BuMA Supreme stent only
Study NCT03168776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience or Promus DES
Description: Implant XIENCE family or Promus family only
Study NCT02755246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyamine supplementation
Description: 3 months of polyamine supplementation (3 capsules/day)
Study NCT02755246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: 3 months of placebo intake (3 capsules/day)
Study NCT00873483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: 0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles
Study NCT00616759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electroconvulsive therapy
Description: electroconvulsive therapy as usual
Study NCT02422420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Use of financial incentives to promote health behaviors.
Study NCT02422420 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial Incentives
Description: Use of financial incentives to promote health behaviors.
Study NCT00226109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: 100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
Study NCT02286414 — intervention group
Intervention type: DRUG
Intervention: Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban
Description: Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban
Study NCT02286414 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonist: warfarin, fluindione, acenocoumarol
Description: Exposure to vitamin K antagonist
Study NCT00111800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.